Trial Profile
Double-blind, parallel-group confirmatory study of AD-810N (zonisamide) in patients with Parkinson's disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Zonisamide (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 21 May 2016 New trial record